2. Danziger N, Sokol ES, Graf RP, et al. Variable landscape of PD-L1 expression in breast carcinoma as detected by the DAKO 22C3 immunohistochemistry assay. Oncologist. 2023;28(4):319–26. 3. Heater NK, Warrior S, Lu J. Current...
10、E.A. Mittendorf, A.V. Philips, F. Meric-Bernstam, N. Qiao, Y. Wu, S. Harrington, X. Su, Y. Wang, A.M. Gonzalez-Angulo, A. Akcakanat, A. Chawla, M. Curran, P. Hwu, P. Sharma, J.K. Litton, J.J. Molldrem, G. Alatrash, PD-L...
Annals of OncologyB. Cerbelli, A. Pernazza, A. Botticelli et al., "PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?" BioMed Research International, vol. 2017, Arti- cle ID 1750925, 7 pages, 2017....
“CD8-positive T cells, in and of themselves, in the absence of PD-L1 immune cell expression, really don’t correlate with clinical benefit,” Emens said. “The money seems to be in PD-L1 expression in the immune cells for selecting patients who can benefit from this chemoimmunotherapy com...
(95% CI 55.2, 83.7). 38 pts had available PD-L1 expression results tested with E1L3N assay. cORR was 76.9% in 13 pts with PD-L1 combined positive score (CPS) < 1 and 72.0% in 25 pts with PD-L1 CPS ≥1. All 9 pts with PD-L1 CPS ≥10 achieved PR. All pts experienced ...
在ADC联合免疫治疗方面,Ib/II期MORPHEUS-panBC研究显示,SG联合阿替利珠单抗用于未接受过系统治疗的PD-L1+、不可手术的局部晚期或转移性TNBC患者,ORR达66.7%,显示了积极的一线治疗潜力[30];在联合靶向治疗方面,SEASTAR研究初步探索了SG联合PARP抑制剂瑞卡帕尼(Rucaparib)的疗效,结果所有3例PARP经治后疾病进展的患者...
在ADC联合免疫治疗方面,Ib/II期MORPHEUS-panBC研究显示,SG联合阿替利珠单抗用于未接受过系统治疗的PD-L1+、不可手术的局部晚期或转移性TNBC患者,ORR达66.7%,显示了积极的一线治疗潜力[30];在联合靶向治疗方面,SEASTAR研究初步探索了SG联合PARP抑制剂瑞卡帕尼(Rucaparib)的疗效,结果所有3例PARP经治后疾病进展的患者...
乳腺癌里面的肿瘤干细胞是妥妥的少数,具有迁移、侵袭、自我更新、复发、耐化疗和放射治疗等多种特性和功能,导致乳腺癌的难治性。 乳腺癌干细胞的异质性和可塑性对其自我更新能力起着重要作用。Differentiated transcription factors can regulate self-renewal and differentiation of BCSCs driven by the core components...
在晚期TNBC的一线治疗中,KEYNOTE-355研究5确立了免疫治疗的地位,帕博利珠单抗联合化疗成为PD-L1 CPS≥10的患者的优选方案;对于gBRCA1/2突变的患者,基于OlympiAD研究6、EMBRACA研究7的表现,PAPR抑制剂奥拉帕利、他拉唑帕利(talazoparib)也成为TNBC一线选择。在晚期TNBC的二线治疗中,ADC也带来了精准治疗的突破,DESTINY-...
在晚期TNBC的一线治疗中,KEYNOTE-355研究5确立了免疫治疗的地位,帕博利珠单抗联合化疗成为PD-L1 CPS≥10的患者的优选方案;对于gBRCA1/2突变的患者,基于OlympiAD研究6、EMBRACA研究7的表现,PAPR抑制剂奥拉帕利、他拉唑帕利(talazoparib)也成为TNBC一线选择。在晚期TNBC的二线治疗中,ADC也带来了精准治疗的突破,DESTINY-...